Promoter holding
64.27%
DP
Dosch Pharmaceuticals Pvt Ltd - Due diligence report
A 360° intelligence report on Dosch Pharmaceuticals Pvt Ltd: trust score, financial health, credit view, compliance, directors, growth and d…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Dosch Pharmaceuticals Pvt Ltd — 360° Intelligence Report
Generated from MCA filings & public records54/100
Trust Score
Moderate
Dosch Pharmaceuticals Pvt Ltd is assessed as Moderate with a Trust Score of 54/100. Dosch Pharmaceuticals Pvt Ltd is a private limited indian non-government company incorporated in 1992, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and moderate financial risk profile.
Report generated on 04 Oct 2026 from the latest processed filings. Dosch Pharmaceuticals Pvt Ltd snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
54/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
16/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
55/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
85/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
40/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
- Negative operating earnings - debt service depends on external support.
- No open charges - unencumbered balance sheet.
Charges position: 0 open (-) · 6 satisfied (177.82 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Infina Finance Private Limited | 1 | 48.0 cr |
| Kotak Mahindra Investments Limited | 1 | 48.0 cr |
| State Bank Of India | 3 | 48.0 cr |
| Citicorp Finance India Limited | 1 | 48.0 cr |
Compliance Score: 16/100 Caution Indicated
- Company status is "Amalgamated" - not Active.
- Last balance sheet is for Mar 2019 - filings overdue.
- Litigation present in 2 court forum(s).
- 1 active GST registration(s).
Legal cases on record (2)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| ASHAY SANJAY DOSHI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SANJAY KANAIYALAL DOSHI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PRACHI SANJAY DOSHI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 3 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2017)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2018 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
4 allotment(s) · 0 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
Key managerial personnel: SANJAY KANAIYALAL DOSHI (Managing Director) · PRACHI SANJAY DOSHI (Whole-time director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 85 · Distress 40
Growth signals & trust indicators
Revenue acceleration: +38% over 4 year(s).
Latest year revenue grew 1.42.
EPFO headcount growing - hiring signal.
Operating for 34+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Losses deepening year-on-year.
Statutory filings appear overdue.
Adverse company status: Amalgamated.
Compliance score is weak (16/100).
2 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence35/100
Caution indicated
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 3 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment41/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- No existing security registered - first-charge position available.
- Compliance gaps should be priced into terms.
Investor view67/100
Mixed indicators
Growth quality and scalability through an investor lens.
- 3 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2019
Last AGM held
Annual general meeting
31 Mar 2019
Latest balance sheet
Filed with ROC
13 Oct 2017
Charge satisfied
Infina Finance Private Limited
Charge satisfied
Kotak Mahindra Investments Limited
Charge satisfied
State Bank Of India
04 Sep 2017
Securities allotted
10000 Preference Shares - 1.00 Lakh raised
01 Apr 2015
Director ceased
RUCHI SANJAY MEHTA
19 Dec 2014
Charge created
Infina Finance Private Limited - 108.00 cr
17 Oct 2014
Charge created
Kotak Mahindra Investments Limited - 40.00 cr
30 Sep 2014
Director ceased
ASHAY SANJAY DOSHI
02 May 2014
Director appointed
ASHAY SANJAY DOSHI (Director)
12 Jul 2012
Charge satisfied
State Bank Of India
26 Jun 2012
Securities allotted
34130 Equity Shares Without Differential Rights - 1.00 cr raised
Charge satisfied
Citicorp Finance India Limited
28 Feb 2011
Securities allotted
25640 Equity Shares Without Differential Rights - 40.00 Lakh raised
10
Key Observations
Auto-generated from the data aboveRevenue grew 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Net worth is positive.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
All 6 registered charge(s) stand satisfied - past borrowings repaid.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2018 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 4 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Cygnus Pharmaceuticals Private Limited | U24231WB1997PTC082943 | Kolkata, West Bengal, India |
| Maximaa Systems | L27100GJ1990PLC014129 | Valsad, Gujarat, India |
| Spirolifecare | U51909MH2011PTC223245 | Mumbai, Maharashtra, India |
| Origin Formulations Private Limited | U24230GJ2010PTC063358 | Ahmedabad, Gujarat, India |
| Apple Lifecare (India) Private Limited | U24230MH2003PTC142920 | Mumbai, Maharashtra, India |
| Unijules Life Sciences | U52311MH2006PLC158928 | Nagpur, Maharashtra, India |
| Makson Industries Private Limited | U24240MP2003PTC035109 | Mandideep, Madhya Pradesh, India |
| Alkameyst Life Private Limited | U74110MH2013PTC245708 | Mumbai, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Dosch Pharmaceuticals Pvt Ltd before audits and certifications: compliance score 16/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Dosch Pharmaceuticals Pvt Ltd: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Enhanced diligence advised. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 85/100, margin trends, ownership structure and peer set for Dosch Pharmaceuticals Pvt Ltd - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Caution indicated. Trust score 54/100, distress signals and MSME payment-delay disclosures - know whether Dosch Pharmaceuticals Pvt Ltd pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Dosch Pharmaceuticals Pvt Ltd - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Dosch Pharmaceuticals Pvt Ltd an active company?
Dosch Pharmaceuticals Pvt Ltd has MCA status “Amalgamated” with a compliance score of 16/100 (Caution Indicated).
Is Dosch Pharmaceuticals Pvt Ltd financially healthy?
Dosch Pharmaceuticals Pvt Ltd has a Financial Health Score of 55/100 (Moderate) based on its filed financial statements.
Should I do business with Dosch Pharmaceuticals Pvt Ltd?
Its overall Trust Score is 54/100 (Moderate). Vendor verdict: Caution indicated. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Dosch Pharmaceuticals Pvt Ltd?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.
Does Dosch Pharmaceuticals Pvt Ltd have loans or charges against its assets?
No open charges - all 6 registered charge(s) stand satisfied, indicating past borrowings were repaid.
Is Dosch Pharmaceuticals Pvt Ltd up to date with its ROC filings?
Last balance sheet is for Mar 2019 - filings overdue. Overall compliance score: 16/100 (Caution Indicated).
Is it risky to lend to Dosch Pharmaceuticals Pvt Ltd?
Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
